Elon Musk 's brain-computer interface company Neuralink announced Monday it has raised $650 million in its latest funding round, as the startup accelerates clinical trials of its brain implant technology across multiple countries.
The Series E round attracted major investors including ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, and several others, valuing the company at approximately $9 billion pre-money according to recent reports. The funding represents a significant increase from Neuralink's $280 million Series D round in August 2023.
Five patients with severe paralysis are currently using Neuralink's brain chip to control digital and physical devices through thought alone, marking a major milestone in the company's mission to restore independence for individuals with neurological conditions. The chip processes neural signals that can be transmitted wirelessly to computers and smartphones.
Clinical trials for Neuralink’s brain implant device expand globally
Neuralink has launched clinical trials at leading medical institutions across three countries, including Barrow Neurological Institute, The Miami Project to Cure Paralysis at the University of Miami, University Health Network in Toronto, and Cleveland Clinic Abu Dhabi.
The FDA granted Neuralink "breakthrough device" designation for both its speech restoration technology last month and its vision-restoring device in 2024. This designation expedites the development and review process for promising medical technologies.
The company plans to use the new funding to expand patient access and develop next-generation devices that create deeper connections between biological and artificial intelligence. Neuralink is also investing in expanding the number of neurons and brain regions its device can interface with, working toward what it calls a "whole-brain interface."
The funding comes as Musk recently stepped back from his advisory role with President Trump to refocus on his companies, including Tesla , SpaceX, and Neuralink.
The Series E round attracted major investors including ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, and several others, valuing the company at approximately $9 billion pre-money according to recent reports. The funding represents a significant increase from Neuralink's $280 million Series D round in August 2023.
Five patients with severe paralysis are currently using Neuralink's brain chip to control digital and physical devices through thought alone, marking a major milestone in the company's mission to restore independence for individuals with neurological conditions. The chip processes neural signals that can be transmitted wirelessly to computers and smartphones.
Clinical trials for Neuralink’s brain implant device expand globally
Neuralink has launched clinical trials at leading medical institutions across three countries, including Barrow Neurological Institute, The Miami Project to Cure Paralysis at the University of Miami, University Health Network in Toronto, and Cleveland Clinic Abu Dhabi.
The FDA granted Neuralink "breakthrough device" designation for both its speech restoration technology last month and its vision-restoring device in 2024. This designation expedites the development and review process for promising medical technologies.
The company plans to use the new funding to expand patient access and develop next-generation devices that create deeper connections between biological and artificial intelligence. Neuralink is also investing in expanding the number of neurons and brain regions its device can interface with, working toward what it calls a "whole-brain interface."
The funding comes as Musk recently stepped back from his advisory role with President Trump to refocus on his companies, including Tesla , SpaceX, and Neuralink.
You may also like
Newark Airport LIVE: All flights grounded sparking travel chaos
Nuke veterans "ghosted" by Keir Starmer as blood scandal grows
BJP indulging in politics over dead bodies: K'taka Dy CM Shivakumar on B'luru stampede tragedy
Campus crackdown: US education department threatens Columbia University's accreditation; cites antisemitism concerns
Blind Date set to return after 22 years off air with huge names eyed up to host
